Targeting the Bombesin/Gastrin-Releasing Peptide Receptor to Treat Sepsis

Author(s): Daniela B. Cornelio, Felipe Dal-Pizzol, Rafael Roesler, Gilberto Schwartsmann

Journal Name: Recent Patents on Anti-Infective Drug Discovery

Volume 2 , Issue 3 , 2007

Become EABM
Become Reviewer

Abstract:

Sepsis is a complex, multifactorial syndrome that can develop into conditions of different severity, described as septic shock or severe sepsis. In spite of the great progress in understanding the mechanisms involved in the pathogenesis and management of sepsis, only a few therapeutic strategies were able to show a decrease in the mortality from septic shock. Although sepsis consists on a systemic inflammatory response, the anti-inflammatory therapies have failed to improve the outcome of critically ill patients. Here the role of gastrin-releasing peptide in immune processes is reviewed and the data that have prompted the recent patent for GRP receptor antagonists RC-3095 as a therapeutic agent on inflammatory conditions are described.

Keywords: Bombesin, gastrin-releasing peptide, GRP, GRPR, sepsis

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 2
ISSUE: 3
Year: 2007
Page: [178 - 181]
Pages: 4
DOI: 10.2174/157489107782497344
Price: $58

Article Metrics

PDF: 3